Table 3.
Distribution of antimicrobial resistance of Salmonella isolated from 2009 to 2012 according to the serovar
| 2009–2012 (No. Isolates) |
SM (%) |
OTC (%) |
SUL (%) |
AMP (%) |
CTX (%) |
CTF (%) |
KM (%) |
CFX (%) |
OFLX (%) |
CP (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Infantis (n = 140) |
132 (94.3) | 122 (87.9) | 121 (86.4) | 41 (29.3) | 36 (25.7) | 34 (25.0) | 13 (8.6) | 15 (10.7) | 3 (2.1) | 0(0.0) |
| Manhattan (n = 98) |
94 (95.9) | 95 (96.9) | 95 (96.9) | 93 (94.9) | 92 (93.9) | 91 (92.9) | 3 (2.0) | 0 (0.0) | 1 (1.0) | 0 (0.0) |
| Schwarzengru-nd (n = 5) | 5 (100) | 5 (100) | 5 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Total (n= 243) |
231 (95.1) | 222 (91.4) | 221 (91.0) | 134 (55.1) | 128 (52.7) | 125 (51.4) | 16 (6.6) | 15 (6.2) | 4 (1.6) | 0 (0.0) |
AMP ampicillin, CTX cefotaxime, CFX cefoxitin, CP chloramphenicol, SM streptomycin, SUL sulfamethoxazole, OTC oxytetracycline, KM kanamycin, OFLX ofloxacin, CTF, ceftiofur